Navigation Links
VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients
Date:5/14/2009

Comprehensive Phase 2 Program Combines Histology, Biomarkers and Non-Invasive Imaging to Demonstrate Mechanism of Action and Positive Impact on Vascular Inflammation

SAN FRANCISCO, May 14 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that it has completed enrollment in a Phase 2 clinical trial of its lead drug, VIA-2291 in patients who have experienced an acute coronary syndrome event such as a heart attack or unstable angina. The randomized, double blind, placebo-controlled study examines the impact of VIA-2291 on plaque inflammation as measured by Positron Emission Tomography with fluorodeoxyglucose tracer (FDG-PET), as well as other standard biomarkers of inflammation, over 24 weeks following such an acute event. A total of 52 patients have been enrolled in the study, which is expected to report data in the second half of 2009.

VIA-2291 is designed to be a selective and reversible inhibitor of 5 Lipoxygenase, a key enzyme in the biosynthesis of leukotrienes, which are important mediators of inflammation believed to be involved in the development and progression of atherosclerosis. The FDG-PET study is the third Phase 2 clinical trial of VIA-2291 conducted by the Company in cardiovascular disease. In addition to being generally well-tolerated, earlier studies reported at the American Heart Association 2008 Scientific Sessions in November 2008, and the American Heart Association Arteriosclerosis, Thrombosis and Vascular Biology Annual Conference 2009 in May 2009, suggest multiple effects of the drug on inflammation, as measured through histology, biomarkers and advanced imaging. These include:

  • Significant, dose dependent, inhib
    '/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Poniard Pharmaceuticals to Present at the Leerink Swann Oncology Roundtable Conference
2. Amylin Pharmaceuticals to Present at Deutsche Bank Health Care Conference
3. Poniard Pharmaceuticals to Present at the 2009 BIO International Convention
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2009 Financial Results on Thursday, May 14, 2009 at 8:30am EDT
5. Arena Pharmaceuticals Announces First Quarter 2009 Financial Results
6. Idenix Pharmaceuticals to Present at The Deutsche Bank 2009 Health Care Conference
7. Quark Pharmaceuticals Presented At ARVO Data Showing That PF-04523655 Enters Retinal Cells And Elicits Its Pharmacologic Effect Via Target Gene Knock-Down Without Activating TLR3
8. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
9. Cadence Pharmaceuticals Reports First Quarter 2009 Financial Results
10. Rib-X Pharmaceuticals Announces Presentations at the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
11. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... , Dec. 22, 2014 /PRNewswire/ - RepliCel Life Sciences ... medicine company focused on the development of autologous cell ... of the University of Calgary in conjunction with co-authors ... which further validates the company,s ongoing clinical research using ... of pattern baldness. The paper entitled " ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 ... peer-reviewed publication of original research, reviews and editorials ... and clinical practice, today published a provocative article ... the development, progression and potential treatment of prostate ... endocrinology research and proposes the possibility that there ...
(Date:12/19/2014)... Charm Sciences is pleased to announce that ... Aflatoxin M1 in raw commingled milk is the first ... The peer reviewed report of the validation by Technology ... and Fisheries Research (ILVO-T&V) has been published by the ... most toxic aflatoxin and a known carcinogen, can be ...
(Date:12/19/2014)... Bina Technologies, Inc. (Bina, Redwood ... have been acquired by Roche (SIX: RO, ROG; OTCQX: ... company that provides a big data platform for centralized ... for the academic and translational research markets.  Bina will ... continue to focus on development of their innovative genomic ...
Breaking Biology Technology:Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... FORT WORTH, Texas, April 14, 2011 The Wound ... forum on dynamic reciprocity at the combined meeting of ... Wound Healing Society (WHS) being held in Dallas at ... 14-17, 2011. Presenting faculty are Dr. Ira M. Herman, ...
... April 14, 2011 Reportlinker.com announces ... is available in its catalogue: ... And Biochips ... Product Development Opportunities and Business Expansion ...
... NEW YORK, April 14, 2011 Reportlinker.com ... is available in its catalogue: ... to 2017 – Neurostimulation Devices, Interventional Neurology ... China-to-2017-–-Neurostimulation-Devices-Interventional-Neurology-and-Other.html Neurology Devices Market Outlook ...
Cached Biology Technology:The Wound Institute® to Feature Educational Forum on Dynamic Reciprocity During the Symposium on Advanced Wound Care and the Wound Healing Society Annual Meeting 2The Wound Institute® to Feature Educational Forum on Dynamic Reciprocity During the Symposium on Advanced Wound Care and the Wound Healing Society Annual Meeting 3The Wound Institute® to Feature Educational Forum on Dynamic Reciprocity During the Symposium on Advanced Wound Care and the Wound Healing Society Annual Meeting 4Reportlinker Adds Molecular Diagnostics Market: DNA Probes And Biochips 2Reportlinker Adds Molecular Diagnostics Market: DNA Probes And Biochips 3Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other 2Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other 3Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other 4Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other 5Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other 6Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other 7Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other 8Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other 9Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other 10Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other 11Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other 12Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other 13
(Date:11/21/2014)... Calif. , Nov. 20, 2014   Atmel® ... leader in microcontroller (MCU) and touch technology solutions, today ... temperature sensors with the widest V cc ... higher temperature accuracy and faster I 2 C bus ... and serial EEPROM memory making them ideal for consumer, ...
(Date:11/18/2014)... BOSTON , Nov. 17, 2014   ... HealthCare and EMC collaborate to develop The Partners ... , The Partners Data Lake will allow ... to improve diagnostics, treatment and the lives of ... support research and clinical activities across the Partners ...
(Date:11/18/2014)... 18, 2014   EyeLock Inc. , a ... MorphoTrust USA (Safran), a leading U.S. ... a strategic partnership to offer comprehensive biometric identity ... (MVA), airport screening and financial services markets. ... serves consumers through a nationwide network of 1,100 ...
Breaking Biology News(10 mins):Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
... years ago, a 71-year-old Indiana man impaled his hand on a ... infection that led scientists to discover a new bacterium and solve ... On Oct. 15, 2010, Thomas Fritz, a retired inventor, engineer and ... his home near Evansville, Ind. As he dragged away the ...
... The question of how life began on a molecular ... mathematical research sheds light on a possible mechanism by which ... that existed on the early Earth. Researchers have proposed ... gotten its start, even before the first genes or living ...
... which are typically only found in fetal development, can become ... can integrate into heart muscle tissue after injection. An ... Although mortality rates are declining, heart attacks are still among ... Often, the cause of a heart attack is the closure ...
Cached Biology News:Microbial 'missing link' discovered after man impales hand on tree branch 2Microbial 'missing link' discovered after man impales hand on tree branch 3Microbial 'missing link' discovered after man impales hand on tree branch 4Model sheds light on the chemistry that sparked the origin of life 2A novel therapeutic advancement in the search for heart muscle progenitor cells 2A novel therapeutic advancement in the search for heart muscle progenitor cells 3A novel therapeutic advancement in the search for heart muscle progenitor cells 4
Zonula Adherens Sampler Kit 10 mu g each...
Purified anti-SOCS3...
Tumor Suppressor Sampler Kit 10 mu g each...
AMAP Multi Site-directed Mutagenesis Kit Research Focus: other Storage Temperature: -20C Shipping Temperature: dry ice...
Biology Products: